Immune cell landscapes are associated with high-grade serous ovarian cancer survival.
Cell ratios
High-grade serous ovarian cancer
Macrophage
Overall survival
T cell activation
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 Jul 2024
12 Jul 2024
Historique:
received:
22
02
2024
accepted:
09
07
2024
medline:
13
7
2024
pubmed:
13
7
2024
entrez:
12
7
2024
Statut:
epublish
Résumé
High-grade serous ovarian cancer (HGSOC) is an aggressive disease known to develop resistance to chemotherapy. We investigated the prognostic significance of tumor cell states and potential mechanisms underlying chemotherapy resistance in HGSOC. Transcriptome deconvolution was performed to address cellular heterogeneity. Kaplan-Meier survival curves were plotted to illustrate the outcomes of patients with varying cellular abundances. The association between gene expression and chemotherapy response was tested. After adjusting for surgery status and grading, several cell states exhibited a significant correlation with patient survival. Cell states can organize into carcinoma ecotypes (CE). CE9 and CE10 were proinflammatory, characterized by higher immunoreactivity, and were associated with favorable survival outcomes. Ratios of cell states and ecotypes had better prognostic abilities than a single cell state or ecotype. A total of 1265 differentially expressed genes were identified between samples with high and low levels of C9 or CE10. These genes were partitioned into three co-expressed modules, which were associated with tumor cells and immune cells. Pogz was identified to be linked with immune cell genes and the chemotherapy response of paclitaxel. Collectively, the survival of HGSOC patients is correlated with specific cell states and ecotypes.
Identifiants
pubmed: 38997411
doi: 10.1038/s41598-024-67213-4
pii: 10.1038/s41598-024-67213-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
16140Subventions
Organisme : Key Research and Development Projects of Hebei Province, China
ID : 19272404D
Informations de copyright
© 2024. The Author(s).
Références
Ciucci, A. et al. Ovarian low and high grade serous carcinomas: Hidden divergent features in the tumor microenvironment. Oncotarget 7, 68033–68043 (2016).
pubmed: 27462782
pmcid: 5356537
doi: 10.18632/oncotarget.10797
Wu, Y. et al. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer. Aging 12, 11398–11415 (2020).
pubmed: 32544083
pmcid: 7343445
doi: 10.18632/aging.103199
Liu, R., Hu, R., Zeng, Y., Zhang, W. & Zhou, H. H. Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study. EBioMedicine 51, 102602 (2020).
pubmed: 31911269
pmcid: 6948169
doi: 10.1016/j.ebiom.2019.102602
Wang, L. et al. T-cell activation is associated with high-grade serous ovarian cancer survival. J. Obstet. Gynaecol. Res. 48, 2189–2197 (2022).
pubmed: 35334503
doi: 10.1111/jog.15234
Konjevic, G. M., Vuletic, A. M., Mirjacic Martinovic, K. M., Larsen, A. K. & Jurisic, V. B. The role of cytokines in the regulation of NK cells in the tumor environment. Cytokine 117, 30–40 (2019).
pubmed: 30784898
doi: 10.1016/j.cyto.2019.02.001
Konjevic, G. et al. Investigation of NK cell function and their modulation in different malignancies. Immunol. Res. 52, 139–156 (2012).
pubmed: 22442005
doi: 10.1007/s12026-012-8285-7
Mirjacic Martinovic, K. et al. Increased circulating TGF-beta1 is associated with impairment in NK cell effector functions in metastatic melanoma patients. Growth Factors 40, 231–239 (2022).
pubmed: 36129407
doi: 10.1080/08977194.2022.2124915
Berry, L., Kelly, M. & Miller, L. Tumor immunogenicity status in high-grade serous ovarian cancer. Gynecol. Oncol. 162, S319 (2021).
doi: 10.1016/S0090-8258(21)01257-9
Chang, H. et al. Construction of a macrophage infiltration regulatory network and related prognostic model of high-grade serous ovarian cancer. J. Oncol. 2021, 1331031 (2021).
pubmed: 34868310
pmcid: 8635947
doi: 10.1155/2021/1331031
Haque, A., Engel, J., Teichmann, S. A. & Lonnberg, T. A practical guide to single-cell RNA-sequencing for biomedical research and clinical applications. Genome Med. 9, 75 (2017).
pubmed: 28821273
pmcid: 5561556
doi: 10.1186/s13073-017-0467-4
Steen, C. B. et al. The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell 39(1422–37), e10 (2021).
Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773–782 (2019).
pubmed: 31061481
pmcid: 6610714
doi: 10.1038/s41587-019-0114-2
Luca, B. A. et al. Atlas of clinically distinct cell states and ecosystems across human solid tumors. Cell 184(5482–96), e28 (2021).
Jurisic, V. Multiomic analysis of cytokines in immuno-oncology. Expert Rev. Proteomics 17, 663–674 (2020).
pubmed: 33131355
doi: 10.1080/14789450.2020.1845654
Huo, J. et al. Gene co-expression analysis identified preserved and survival-related modules in severe blunt trauma, burns, sepsis, and systemic inflammatory response syndrome. Int. J. Gen. Med. 14, 7065–7076 (2021).
pubmed: 34707398
pmcid: 8544272
doi: 10.2147/IJGM.S336785
Garsed, D. W. et al. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. Nat. Genet. 54, 1853–1864 (2022).
pubmed: 36456881
pmcid: 10478425
doi: 10.1038/s41588-022-01230-9
Yoshihara, K. et al. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin. Cancer Res. 18, 1374–1385 (2012).
pubmed: 22241791
doi: 10.1158/1078-0432.CCR-11-2725
Consortium GT. (2015) Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans. Science 348, 648–60 (2015).
doi: 10.1126/science.1262110
Liu, J. et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173, 400–416 (2018).
pubmed: 29625055
pmcid: 6066282
doi: 10.1016/j.cell.2018.02.052
Bartha, A. & Gyorffy, B. TNMplot.com: A web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int. J. Mol. Sci. 22, 2622 (2021).
pubmed: 33807717
pmcid: 7961455
doi: 10.3390/ijms22052622
Gyorffy, B. Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. Geroscience 45, 1889–1898 (2023).
pubmed: 36856946
pmcid: 10400493
doi: 10.1007/s11357-023-00742-4
Fekete, J. T. & Gyorffy, B. ROCplot.org: Validating predictive biomarkers of chemotherapy/hormonal therapy/anti-HER2 therapy using transcriptomic data of 3104 breast cancer patients. Int. J. Cancer 145, 3140–51 (2019).
pubmed: 31020993
doi: 10.1002/ijc.32369
Langfelder, P. & Horvath, S. WGCNA: An R package for weighted correlation network analysis. BMC Bioinform. 9, 559 (2008).
doi: 10.1186/1471-2105-9-559
Lai, X. et al. Reference module-based analysis of ovarian cancer transcriptome identifies important modules and potential drugs. Biochem. Genet. 60, 433–451 (2022).
pubmed: 34173117
doi: 10.1007/s10528-021-10101-7
Wu, T. et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation 2, 100141 (2021).
pubmed: 34557778
pmcid: 8454663
Bos, L. D. J. et al. Understanding heterogeneity in biologic phenotypes of acute respiratory distress syndrome by leukocyte expression profiles. Am. J. Respir. Crit. Care Med. 200, 42–50 (2019).
pubmed: 30645145
doi: 10.1164/rccm.201809-1808OC
Paci, P. et al. Gene co-expression in the interactome: Moving from correlation toward causation via an integrated approach to disease module discovery. npj Syst. Biol. Appl. 7, 3 (2021).
pubmed: 33479222
pmcid: 7819998
doi: 10.1038/s41540-020-00168-0
Li, T. et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48, W509–W14 (2020).
pubmed: 32442275
pmcid: 7319575
doi: 10.1093/nar/gkaa407
Schweer, D. et al. Tumor-associated macrophages and ovarian cancer: Implications for therapy. Cancers 14, 2220 (2022).
pubmed: 35565348
pmcid: 9101750
doi: 10.3390/cancers14092220
Tan, J. K. & O’Neill, H. C. Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity. J. Leukoc. Biol. 78, 319–324 (2005).
pubmed: 15809288
doi: 10.1189/jlb.1104664
Chaudhry, M. S. et al. Missense mutations in the perforin (PRF1) gene as a cause of hereditary cancer predisposition. Oncoimmunology 5, e1179415 (2016).
pubmed: 27622035
pmcid: 5006901
doi: 10.1080/2162402X.2016.1179415
Wang, C. H. et al. TIG1 inhibits the mTOR signaling pathway in malignant melanoma through the VAC14 protein. Anticancer Res. 43, 2635–2643 (2023).
pubmed: 37247911
doi: 10.21873/anticanres.16430
Watanabe, M. et al. Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma. Br. J. Cancer 102, 520–529 (2010).
pubmed: 20029417
doi: 10.1038/sj.bjc.6605502
Vales-Gomez, M. et al. Natural killer cell hyporesponsiveness and impaired development in a CD247-deficient patient. J. Allergy Clin. Immunol. 137(942–5), e4 (2016).
Morgan, T. K. et al. Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: An immunohistochemical analysis. Am. J. Clin. Pathol. 126, 545–551 (2006).
pubmed: 16938662
doi: 10.1309/ELGMGX81C2UTP55R
Jurisic, V., Bogdanovic, G., Kojic, V., Jakimov, D. & Srdic, T. Effect of TNF-alpha on Raji cells at different cellular levels estimated by various methods. Ann. Hematol. 85, 86–94 (2006).
pubmed: 16261372
doi: 10.1007/s00277-005-0010-3
Mirjacic Martinovic, K. et al. Increased circulating monocyte MDSCs positively correlate with serum Interleukin-10 in metastatic melanoma patients. Innate Immun. 29, 37–44 (2023).
pubmed: 37160888
pmcid: 10331212
doi: 10.1177/17534259231172079
Hu, Z. & Zhou, G. CREB1 transcriptionally activates LTBR to promote the NF-kappaB pathway and apoptosis in lung epithelial cells. Comput. Math. Methods Med. 2022, 9588740 (2022).
pubmed: 36118831
pmcid: 9481394
doi: 10.1155/2022/9588740
Jurisic, V., Colovic, N., Konjevic, G., Minic, I. & Colovic, M. An aggressive extramedullary cutaneous plasmacytoma associated with extreme alterations in the innate immune system. Onkologie 33, 113–115 (2010).
pubmed: 20215803
doi: 10.1159/000278713
Jurisic, V., Stojacic-Djenic, S., Colovic, N. & Konjevic, G. The role of cytokine in regulation of the natural killer cell activity. Srp. Arh. Celok. Lek. 136, 423–429 (2008).
pubmed: 18959181
doi: 10.2298/SARH0808423J
Zhang, M. et al. A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J. Ovarian Res. 7, 19 (2014).
pubmed: 24507759
pmcid: 3939626
doi: 10.1186/1757-2215-7-19
Oshi, M. et al. M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer. Sci. Rep. 10, 16554 (2020).
pubmed: 33024179
pmcid: 7538579
doi: 10.1038/s41598-020-73624-w
Mirjacic Martinovic, K. et al. Circulating cytokine dynamics as potential biomarker of response to anti-PD-1 immunotherapy in BRAFwt MM patients. Transl. Oncol. 38, 101799 (2023).
pubmed: 37806113
pmcid: 10579527
doi: 10.1016/j.tranon.2023.101799
Kandalaft, L. E., Dangaj Laniti, D. & Coukos, G. Immunobiology of high-grade serous ovarian cancer: Lessons for clinical translation. Nat. Rev. Cancer 22, 640–656 (2022).
pubmed: 36109621
doi: 10.1038/s41568-022-00503-z
Sakuma, M. et al. A potential biomarker of dynamic change in peripheral CD45RA(-)CD27(+)CD127(+) central memory T cells for anti-PD-1 therapy in patients with esophageal squamous cell carcinoma. Cancers 15, 3641 (2023).
pubmed: 37509302
pmcid: 10377516
doi: 10.3390/cancers15143641
Fujiwara, T. et al. CSF1/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment. Mol. Cancer Ther. 20, 1388–1399 (2021).
pubmed: 34088832
pmcid: 9336538
doi: 10.1158/1535-7163.MCT-20-0591